OKYO Pharma Limited has filed its annual report on Form 20-F for the fiscal year ended March 31, 2026, with the US Securities ...
The approval establishes LYTENAVA as the first and only FDA-approved ophthalmic formulation of bevacizumab for the treatment ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results